Background:Evolocumab,a fully human monoclonal antibody directed against proprotein convertase subtilisin-kexin type 9,is widely used in adult patients to lower low-density lipoprotein(LDL)cholesterol levels.Its effec...Background:Evolocumab,a fully human monoclonal antibody directed against proprotein convertase subtilisin-kexin type 9,is widely used in adult patients to lower low-density lipoprotein(LDL)cholesterol levels.Its effects in pediatric patients with heterozygous familial hypercholesterolemia are not known.Methods:We conducted a 24-week,randomized,double-blind,placebo-controlled trial to evaluate the efficacy and safety of evolocumab in pediatric patients with heterozygous familial hypercholesterolemia.Patients 10 to 17 years of age who had received stable lipid-lowering treatment for at least 4 weeks before screening and who had an LDL cholesterol level of 130 mg per deciliter(3.4 mmol per liter)or more and a triglyceride level of 400 mg per deciliter(4.5 mmol per liter)or less were randomly assigned in a 2:1 ratio to receive monthly subcutaneous injections of evolocumab(420 mg)or placebo.The primary end point was the percent change in LDL cholesterol level from baseline to week 24;key secondary end points were the mean percent change in LDL cholesterol level from baseline to weeks 22 and 24 and the absolute change in LDL cholesterol level from baseline to week 24.展开更多
文摘Background:Evolocumab,a fully human monoclonal antibody directed against proprotein convertase subtilisin-kexin type 9,is widely used in adult patients to lower low-density lipoprotein(LDL)cholesterol levels.Its effects in pediatric patients with heterozygous familial hypercholesterolemia are not known.Methods:We conducted a 24-week,randomized,double-blind,placebo-controlled trial to evaluate the efficacy and safety of evolocumab in pediatric patients with heterozygous familial hypercholesterolemia.Patients 10 to 17 years of age who had received stable lipid-lowering treatment for at least 4 weeks before screening and who had an LDL cholesterol level of 130 mg per deciliter(3.4 mmol per liter)or more and a triglyceride level of 400 mg per deciliter(4.5 mmol per liter)or less were randomly assigned in a 2:1 ratio to receive monthly subcutaneous injections of evolocumab(420 mg)or placebo.The primary end point was the percent change in LDL cholesterol level from baseline to week 24;key secondary end points were the mean percent change in LDL cholesterol level from baseline to weeks 22 and 24 and the absolute change in LDL cholesterol level from baseline to week 24.
